ARTICLE | Finance
Hitting a triple
DRI Capital raises $701M in drug royalty fund
April 12, 2010 7:00 AM UTC
DRI Capital closed its Drug Royalty II at $701 million last week, almost triple the $240 million raised in its 2006 fund, Drug Royalty I.
The firm's strategy will remain the same: purchasing royalties on approved biopharmaceutical products with demonstrated sales histories, according to Alex Leykikh of Atlantic-Pacific Capital. Atlantic-Pacific was the global placement agent and advisor...